Rapid and Efficient Gene Editing for Direct Transplantation of Naive Murine Cas9+ T Cells

Language
en
Document Type
Article
Issue Date
2021-08-04
First published
2021-07-21
Issue Year
2021
Authors
Majumder, Snigdha
Jugovic, Isabelle
Saul, Domenica
Bell, Luisa
Hundhausen, Nadine
Seal, Rishav
Beilhack, Andreas
Rosenwald, Andreas
Mougiakakos, Dimitrios
Berberich-Siebelt, Friederike
Editor
Publisher
Frontiers Media S.A.
Abstract

Gene editing of primary T cells is a difficult task. However, it is important for research and especially for clinical T-cell transfers. CRISPR/Cas9 is the most powerful gene-editing technique. It has to be applied to cells by either retroviral transduction or electroporation of ribonucleoprotein complexes. Only the latter is possible with resting T cells. Here, we make use of Cas9 transgenic mice and demonstrate nucleofection of pre-stimulated and, importantly, of naive CD3+ T cells with guideRNA only. This proved to be rapid and efficient with no need of further selection. In the mixture of Cas9+CD3+ T cells, CD4+ and CD8+ conventional as well as regulatory T cells were targeted concurrently. IL-7 supported survival and naivety in vitro, but T cells were also transplantable immediately after nucleofection and elicited their function like unprocessed T cells. Accordingly, metabolic reprogramming reached normal levels within days. In a major mismatch model of GvHD, not only ablation of NFATc1 and/or NFATc2, but also of the NFAT-target gene IRF4 in naïve primary murine Cas9+CD3+ T cells by gRNA-only nucleofection ameliorated GvHD. However, pre-activated murine T cells could not achieve long-term protection from GvHD upon single NFATc1 or NFATc2 knockout. This emphasizes the necessity of gene-editing and transferring unstimulated human T cells during allogenic hematopoietic stem cell transplantation.

Journal Title
Frontiers in Immunology
Volume
12
Citation
Frontiers in Immunology 12 (2021): 683631. <https://www.frontiersin.org/articles/10.3389/fimmu.2021.683631/full>
Zugehörige ORCIDs